

FIG. 4. **Ndr2 protein and precipitation of actin.** (A) Ndr2 was detected in 100 μg of total brain homogenate using $Ab^{420-430}$. In addition to a signal at the predicted molecular mass of 54kD, background staining of several high and low molecular weight proteins was seen in all SDS-PAGE preparations. The lanes on the right show purified Ndr2 protein from the brain and bacterial MBP::Ndr2 fusion protein. (B) Pull down assays with MBP::Ndr2 fusion proteins precipitated β-actin from brain protein extracts. Only traces of β-actin were seen in MBP precipitates or after omission of amylose. In contrast, we entirely failed to detect β-tubulin or neurofilament proteins in MBP::Ndr2 precipitates. For both, crude brain protein extracts served as positive controls. *NF-L*, neurofilament light chain. *C*, β-actin was also co-precipitated with Ndr2 through $Ab^{420-430}$, whereas only background actin labeling was observed when the primary antibody was omitted. Analysis of precipitates with phospho-serine antibodies further suggests that a considerable proportion of the precipitated β-actin was phosphorylated.

EGFP::Ndr2-transfected cells (78.1 ± 22.1%) compared with *EGFP* controls (91.0 ± 5.4%). Ser^{282}/Thr^{442} double mutants showed intermediate values (82.9 ± 4.5%). The length of neurites (mean ± S.D. of cells with total neurite length of >100 μm: *EGFP::Ndr2* 216.7 ± 64.6 μm, control *EGFP* 222.4 ± 84.6 μm) and their branching pattern (*i.e.* frequency of first, second, and third order branches) did not differ. To address putative mechanisms of Ndr2 function, we determined protein serine phosphorylation in PC12 cells on the first day of neurite outgrowth, *i.e.* before their development of significant differences in neurite length. In our immunoblot analyses we could distinguish at least eight major phospho-serine protein bands, two of which with molecular weights of 36 and 42 kDa showed a higher degree of serine phosphorylation in Ndr2-expressing cultures than in EGFP and mutant Ndr2 controls (Fig. 5*D*). Quantification in triplicate experiments showed an increase of the 42-kDa band to 218.7 ± 45.1% of baseline values (*i.e.* in floating cells) in *EGFP::Ndr2*-transfected cells, but no change from baseline in phosphorylation of EGFP or Ser^{282}/Thr^{442} mutant controls (96.0 ± 10.6% and 82.9 ± 18.7%, respectively; between group comparison: $p < 0.05$). A similar, but not statistically significant change was observed for the 36-kDa signal (EGFP::Ndr2: 273.6 ± 151.5%, EGFP controls: 93.9 ± 50.9% mutant controls: 57.4 ± 19.6%). Furthermore, a reduced phosphorylation of a double band at ~100 kDa was observed independently of neurite outgrowth in *EGFP::Ndr2*-transfected cells (49.3 ± 17.3% of control cell levels; $p < 0.05$), but not in Ser^{282}/Thr^{442} mutant controls (100.2 ± 28.1% of control cell levels).

Acute Transfection—Acute EGFP::Ndr2-transfected cells also showed a greatly reduced adhesion and spreading on the substrate (4.8 ± 3.0% with NGF, 3.3 ± 3.3% without NGF), compared with cells transfected with EGFP (35.5 ± 8.3% with NGF, 16.7 ± 8.6% without NGF, $p < 0.01$ for both). In fact, cells with the highest expression of EGFP::Ndr2 did not even attach to the dish in these experiments. Mutated EGFP::Ndr2 had no such effect (27.2 ± 6.0% with NGF, 15.5 ± 5.0% without NGF). At the same time we observed a reduction of neurite outgrowth ($p < 0.01$) in acutely EGFP::Ndr2-transfected cells (7.1 ± 7.0% with NGF, 3.3 ± 3.3% without NGF) compared with EGFP (55.4 ± 7.0% with NGF, 23.8 ± 9.9% without NGF, $p < 0.01$ for both), contrasting the enhancement of neurite outgrowth in stably transfected cell lines. Mutated EGFP::Ndr2 showed intermediate effects depending on the stimulation with NGF (35.1 ± 9.0% with NGF, $p < 0.01$; 6.7 ± 5.1% without NGF, not significant).

DISCUSSION

To address the cellular and molecular processes that underlie memory consolidation and neural plasticity, we study gene products that are expressed in the mouse amygdala after classic fear conditioning (2). Here we describe the cloning and functional characterization of a novel serine/threonine kinase expressed in the brain, Ndr2 (Stk38l), the expression of which is transiently increased in the amygdala during the consolidation of Pavlovian fear memory. Our experiments provide evidence for an interaction of Ndr2 with the actin cytoskeleton and its putative involvement in control of cell morphology and differentiation in neuronal and neuronal-like cells.

A fragment of the *Ndr2* 3′-untranslated region was obtained through subtractive hybridization cloning from the amygdala of fear-conditioned mice (2). PCR-based gene expression analysis confirmed that *Ndr2* transcript levels were transiently elevated in the amygdala of fear-conditioned and pseudo-conditioned animals 6 h after training and returned to baseline within 24 h. Thus, during consolidation of fear memory, *Ndr2* mRNA levels are regulated in the basolateral complex of the amygdala in a learning- and stress-dependent manner, similar to several other signal transduction and structural re-organization factors (2). GenBank™ analysis suggests that transcription of the *Ndr2* gene may be driven through cyclic AMP response elements (CRE) or serum-responsive elements. These are potential targets for the CRE-binding protein CREB and the mitogen-activated protein kinase pathway in amygdala neurons, respectively, which may explain the observed induction of gene expression after fear conditioning training.

Moderate induction of *Ndr2* in two other areas concerned with fear memory, the frontal cortex, and the hippocampus (after pseudo-conditioning), indicates a more general role in information storage in the fear-conditioning circuits and should prompt further investigation. For example, a tendency for increased *Ndr2* expression in the hippocampus of pseudo-conditioned animals may relate to a preferential storage of contextual information in this training group. Due to a considerable baseline expression and apparently distributed induction after fear conditioning, changes in the expression of Ndr2 could not



FIG. 5. **Ndr2 facilitates neurite outgrowth in the absence of NGF and reduces cell spreading on the substrate.** *Photographs* in *A* show representative examples of EGFP::Ndr2-transfected cells and EGFP-transfected control cells, grown for 1 day (*1d*) or 3 days (*3d*) in the absence, or for 3 days in the presence of NGF (*3d NGF*). The *graphs* summarize the difference between experimental groups in neurite outgrowth (*B*) and cell spreading (*C*; $n = 6$). Increased neurite growth was particularly evident on day 3 without NGF treatment. On the other hand, a reduction of cell spreading was seen both in the presence and absence of NGF. Both effects were abolished in cells expressing mutated Ndr2. *D*, increased protein serine phosphorylation was evident during neurite outgrowth in cells transfected with EGFP::Ndr2. *Arrows* indicate two proteins with molecular masses of ~36 and 42 kDa that showed consistently increased phosphorylation and a double band at ~100 kDa with reduced phosphorylation compared with controls. The *graph* presents the increase of β-actin phosphorylation in different lines, compared with baseline levels (mean ± S.E., $n = 3$).

be visualized by *in situ* hybridization or immunohistochemistry. In fact, expression of Ndr2 was also observed in various cortical and subcortical brain areas that do not relate to the fear conditioning circuitry (Fig. 2).

Ndr1 and Ndr2 belong to a family of growth-related protein kinases, which are involved in proliferation and cellular differentiation in yeast, *Caenorhabditis elegans*, *Drosophila melanogaster*, and mammals (11). Several lines of evidence indicate that molecular processes of growth and structural re-organization indeed occur in the mammalian amygdala during consolidation of fear memory (16). In particular, these may involve modifications at the actin cytoskeleton, which are critical for neural plasticity and memory formation (9). Previous observations of a differential expression of actin isoforms (2) and the activation of $p160^{ROCK}$ (8) in the amygdala during or following fear conditioning support this view. Findings in other organisms indicate that Ndr kinases may be involved in pathways that control such actin filament dynamics: the Ndr kinase orthologue in *D. melanogaster*, *Triconcerned*, interacts with the actin cytoskeleton and co-ordinates growth of actin filaments (17), and the Ndr kinase orthologue in *C. elegans*, SAX-1, shares function with the RhoA-GTPase signaling pathway during neurite formation (18). We, therefore, focused our analysis of Ndr2 function on a potential association with the actin cytoskeleton and on actin-mediated functions in a cellular model of neuronal differentiation.

As a first step, we determined the intracellular localization of EGFP::Ndr2 fusion proteins in differentiated PC12 cells and acutely isolated cortical neurons. We could show that EGFP::Ndr2 co-localizes with actin filaments at the somata, at some sites of cell contact including synapses, at the growth cones and filopodia of PC12 cells, as well as in dendrites, spines, and outgrowing axons of cortical neurons. This labeling pattern matches the distribution of Ndr2 immunohistochemical preparations from the brain and was sensitive to disruption of actin filaments with latrunculin B. Data from our immunoprecipitation and pull-down experiments indicate that Ndr2 is indeed able to bind (phospho-) actin. Interestingly, highly overexpressing cells showed an accumulation of EGFP::Ndr2 in granule-like structures similar to those reported recently by Devroe and co-workers (13), in addition to actin filaments. The composition of these granular structures and the mechanisms of Ndr2 association with different intracellular compartments remain to be investigated.

In the course of our localization experiments we also obtained evidence for an involvement of Ndr2 in actin-mediated cellular functions, in that cells expressing EGFP::Ndr2 displayed consistently reduced spreading on the substrate. Spreading of PC12 cells, *e.g.* after RhoA activation, is typically accompanied by the formation of focal adhesions and stress fibers (19). However, focal adhesions generally were devoid of EGFP::Ndr2 in our experiments. This exclusion from stabilized contact sites and the reduced spreading suggest that Ndr2 may negatively regulate substrate adhesion in differentiated PC12 cells, possibly by reducing the stability of actin-dependent contact sites. Reduced PC12 cell adhesion, by virtue of a reduced contact inhibition, may also explain the increased proliferation of these cells (20) in line with the observation that inhibition of the potential Ndr-kinase activator S100B (21) both induces flattening of glia cells and reduces their proliferation (22).

Some S100 proteins are also potent inducers of neurite outgrowth (23). In fact, we found that EGFP::Ndr2 in stably transfected cell lines facilitated the formation of short neuritic processes in the absence of NGF, although it did not enhance NGF-induced outgrowth nor affect the length or complexity of neuritic trees in NGF-treated cells. Acutely transfected cells on the contrary showed reduced neurite outgrowth both in the presence and absence of NGF.

We believe that facilitation of neurite outgrowth through Ndr2 is limited by the simultaneous reduction of matrix adhesion, and that high expression levels after acute transfection precluded neurite outgrowth in our experiments. This can be explained with an enhancement of actin dynamics through Ndr2 resulting in competing cellular effects. The kinase appears to be well suited to translate Ca^{2+} signals, which are critical for both NGF-dependent and NGF-independent neurite

outgrowth, to the actin cytoskeleton (12). In fact, several conserved regulatory amino acid motifs indicate that the Ndr2 protein is a site of convergence for Ca^{2+}/S100, protein kinase A, and mitogen-activated protein kinase signaling pathways, all of which are involved in neurite outgrowth in PC12 cells (22–25), as well as amygdalar processes during fear memory consolidation (reviewed in Ref. 4).

In support of this view we finally found that the facilitatory effect of Ndr2 on NGF-independent neurite outgrowth was preceded by increases of phosphorylation in at least two proteins, one of which co-migrated with β-actin. We are currently identifying hyperphosphorylated proteins in Ndr2-expressing cells and investigating their role in Ndr2-induced neurite outgrowth. So far we could show that Ndr2-mediated cellular effects are dependent on its kinase activity: double mutation of the activity-controlling phosphorylation sites at Ser^{282} and at Thr^{442} (12) counteracted the Ndr2-induced reduction of cell spreading and changes in neurite outgrowth, as well as associated changes in protein phosphorylation. Protein kinases and phosphatases play key roles in cytoskeleton re-arrangement during cellular growth and differentiation. For example, phosphorylation through protein kinase A has been shown to stabilize actin monomers and to prevent filament formation, whereas protein kinase C increases the incorporation of actin into filaments (26, 27). Our data indicate that Ndr2 by controlling actin phosphorylation and actin filament dynamics may play an important role in cell adhesion and neurite outgrowth.

Several molecular and cellular processes have been identified that are involved in increased activity and synchronization of projection neurons in the lateral amygdala after fear conditioning (4). Other molecular changes provide evidence for learning-related structural plasticity in the amygdala (16). However, memory-related synaptogenesis or changes in spine density like in the hippocampus (28, 29) have not yet been demonstrated in the amygdala. Its widespread expression in the brain, the learning-coordinated induction in the amygdala, and its molecular characteristics make Ndr2 a highly interesting molecular target for the analysis of actin-mediated cellular processes related to morphological re-organization and fear memory consolidation.

Acknowledgments—We thank Margit Schmidt, Sandra Vorwerk, and Simone Stork for expert technical assistance and are grateful to Dr. Thomas Dresbach and Dr. Peter Landgraf for help with cell culture experiments.

REFERENCES

1. Kandel, E. R. (2001) *Science* **294**, 1030–1038
2. Stork, O., Stork, S., Pape, H.-C., and Obata, K. (2001) *Learn. Mem.* **8**, 209–219
3. LeDoux, J. E. (2000) *Annu. Rev. Neurosci.* **23**, 155–184
4. Stork, O., and Pape, H.-C. (2002) *Cell Tissue Res.* **310**, 271–277
5. Schafe, G. E., Atkins, C. M., Swank, M. W., Bauer, E. P., Sweatt, J. D., and LeDoux, J. E. (2000) *J. Neurosci.* **20**, 8177–8187
6. Schafe, G. E., and LeDoux, J. E. (2000) *J. Neurosci.* **20**, RC96
7. Moita, M. A., Lamprecht, R., Nader, K., and LeDoux, J. E. (2002) *Nature Neurosci.* **5**, 837–838
8. Lamprecht, R., Farb, C. R., and LeDoux, J. E. (2002) *Neuron* **36**, 727–738
9. Matus, A. (2000) *Science* **290**, 754–758
10. Bonhoeffer, T., and Yuste, R. (2002) *Neuron* **35**, 1019–1027
11. Tamaskovic, R., Bichsel, S. J., and Hemmings, B. A. (2003) *FEBS Lett.* **546**, 73–80
12. Stegert, M. R., Tamaskovic, T., Bichsel, S. J., Hergovich, A., and Hemmings, B. A. (2004) *J. Biol. Chem.* **279**, 23806–23812
13. Devroe, E., Erdjument-Bromage, H., Tempst, P., and Silver, P. A. (2004) *J. Biol. Chem.* **279**, 24444–24451
14. Yoshikawa, T., Sanders, A. R., Esterling, L. E., Overhauser, J., Garnes, J. A., Lennon, G., Grewal, R., and Detera-Wadleigh, S. D. (1997) *Am. J. Med. Genet.* **74**, 140–149
15. Goslin, K., Asmussen, H., and Banker, G. (1998) in *Culturing Nerve Cells* (Banker, G., and Goslin, K., eds) pp 339–370, MIT Press, Cambridge, MA
16. Lamprecht, R., and LeDoux, J. E. (2003) *Nat. Rev. Neurosci.* **5**, 45–54
17. Geng, W., He, B., Wang, M., and Adler, P. N. (2000) *Genetics* **156**, 1817–1828
18. Zallen, J. A., Peckol, E. L., Tobin, D. M., and Bargmann, C. I. (2000) *Mol. Biol. Cell* **11**, 3177–3190
19. Altun-Gultekin, Z. F., Chandriani, S., Bougeret, C., Ishizaki, T., Narumiya, S., de Graaf, P., Van Bergen en Henegouwen, P., Hanafusa, H., Wagner, J. A., and Birge, R. B., (1998) *Mol. Cell. Biol.* **18**, 3044–3058
20. Pawlak, G., and Helfman, D. M. (2001) *Curr. Opin. Genet. Dev.* **11**, 41–47
21. Millward, T. A., Heizmann, C. W., Schäfer, B. W., and Hemmings, B. A. (1998) *EMBO J.* **17**, 5913–5922
22. Selinfreund, R. H., Barger, S. W., Welsh, M. J., and Van Eldik, L. J. (1990) *J. Cell Biol.* **111**, 2021–2028
23. Mikkelsen, S. E., Novitskaya, V., Kriajevska, M., Berezin, V., Bock, E., Norrild, B., and Lukanidin, E. (2001) *J. Neurochem.* **79**, 767–776
24. Huang, C. M., Tsay, K. E., and Kao, L. S. (1996) *J. Neurochem.* **67**, 530–539
25. Rusanescu, G., Qi, H., Thomas, S. M., Brugge, J. S., and Halegoua, S. (1995) *Neuron* **15**, 1415–1425
26. Ohta, Y., Akiyama, T., Nishida, E., and Sakai, H. (1987) *FEBS Lett.* **222**, 305–310
27. Prat, A. G., Bertorello, A. M., Ausiello, D. A., and Cantiello, H. F. (1993) *Am. J. Physiol.* **265**, 224–233
28. O'Malley, A., O'Connell, C., and Regan, C. M. (1998) *Neuroscience* **87**, 607–613
29. Geinisman, Z., Berry, R. W., Disterhoft, J. F., Power, J. M., and Van der Zee, E. A. (2001) *J. Neurosci.* **21**, 5568–5573

ELSEVIER

Available online at www.sciencedirect.com

SCIENCE DIRECT®

Genomics 84 (2004) 1041–1050

GENOMICS

www.elsevier.com/locate/ygeno

Mitochondrial DNA 3644T→C mutation associated with bipolar disorder

Kae Munakata[a], Masashi Tanaka[b], Kanako Mori[a], Shinsuke Washizuka[a], Makoto Yoneda[c], Osamu Tajima[d], Tsuyoshi Akiyama[e], Shinichiro Nanko[f], Hiroshi Kunugi[g], Kazuyuki Tadokoro[g], Norio Ozaki[h], Toshiya Inada[h], Kaoru Sakamoto[i], Takako Fukunaga[i], Yoshimi Iijima[j], Nakao Iwata[k], Masahiko Tatsumi[l], Kazuo Yamada[m], Takeo Yoshikawa[m], Tadafumi Kato[a,*]

[a]*Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Brain Science Institute, Hirosawa 2-1, Wako, Saitama 351-0198, Japan*
[b]*Department of Gene Therapy, Gifu International Institute of Biotechnology, Gifu, Japan*
[c]*Department of Internal Medicine, Fukui Medical University, Fukui, Japan*
[d]*Kyorin University School of Health Sciences, Kyorin, Japan*
[e]*Department of Neuropsychiatry, NTT East Kanto Medical Center, Kanto, Japan*
[f]*Department of Psychiatry, Teikyo University School of Medicine, Teikyo, Japan*
[g]*Department of Mental Disorder Research, National Institute of Neuroscience, Tokyo, Japan*
[h]*Department of Psychiatry, Faculty of Medicine, Nagoya University, Nagoya, Japan*
[i]*Department of Psychiatry, Tokyo Women's Medical College, Tokyo, Japan*
[j]*National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan*
[k]*Department of Psychiatry, Faculty of Medicine, Fujita Health University, Fujita, Japan*
[l]*Department of Psychiatry, Faculty of Medicine, Showa University, Showa, Japan*
[m]*Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, Hirosawa 2-1, Wako, Saitama 351-0198, Japan*

Received 11 June 2004; accepted 18 August 2004
Available online 17 September 2004

Abstract

Mitochondrial dysfunction associated with mutant mitochondrial DNA (mtDNA) has been suggested in bipolar disorder, and comorbidity with neurodegenerative diseases was often noted. We examined the entire sequence of mtDNA in six subjects with bipolar disorder having comorbid somatic symptoms suggestive of mitochondrial disorders and found several uncharacterized homoplasmic nonsynonymous nucleotide substitutions of mtDNA. Of these, 3644C was found in 5 of 199 patients with bipolar disorder but in none of 258 controls (p = 0.015). The association was significant in the extended samples [bipolar disorder, 9/630 (1.43%); controls, 1/734 (0.14%); p = 0.007]. On the other hand, only 5 of 25 family members with this mutation developed bipolar disorder, of which 4 patients with 3644C had comorbid physical symptoms. The 3644T→C mutation converts amino acid 113, valine, to alanine in the NADH-ubiquinone dehydrogenase subunit I, a subunit of complex I, and 113 valine is well conserved from *Drosophila* to 61 mammalian species. Using transmitochondrial cybrids, 3644T→C was shown to decrease mitochondrial membrane potential and complex I activity compared with haplogroup-matched controls. According to human mitochondrial genome polymorphism databases, 3644C was not found in centenarians but was found in 3% of patients with Alzheimer disease and 2% with Parkinson disease. The result of modest functional impairment caused by 3644T→C suggests that this mutation could increase the risk for bipolar disorder.
© 2004 Elsevier Inc. All rights reserved.

Keywords: Bipolar disorder; MtDNA 3644T→C; Association study; Mitochondrial membrane potential; Complex I activity

Bipolar disorder is a major mental disorder characterized by recurrent manic and depressive episodes affecting about 1% of the population. The contribution of multiple genetic factors in the etiology of bipolar disorder is known from studies of twins, adoptions, and families. Although recent

* Corresponding author. Fax: +81 48 467 6947.
E-mail address: kato@brain.riken.go.jp (T. Kato).

0888-7543/$ - see front matter © 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygeno.2004.08.015

studies suggested several candidate polymorphisms, such as Val 311 of the brain-derived neurotrophic factor [1,2] and the −116G polymorphism of X-box binding protein 1 [3], the pathophysiological mechanisms of bipolar disorder have not yet been totally elucidated. Mitochondrial dysfunction in bipolar disorder was initially suggested by altered brain energy metabolism detected by ^{31}P magnetic resonance spectroscopy [4] and was recently supported by the altered gene expressions of mitochondria-related genes revealed by DNA microarray analysis in the postmortem brain [5]. The comorbidity of bipolar disorder or depression and a mitochondrial disorder, chronic-progressive external ophthalmoplegia (CPEO) [6–8], also suggests that mitochondrial dysfunction can cause bipolar disorder. It was pointed out that some families of bipolar disorder were seen in the maternal lineage [9], suggesting that mitochondrial DNA may have a pathophysiological role in bipolar disorder. The authors previously reported an association between bipolar disorder and two mitochondrial DNA (mtDNA) polymorphisms, 5178C and 10398A, in Japanese subjects [10]. A similar trend of association with 10398A was also reported in Caucasians [11]. These two polymorphisms convert amino acids in the subunits of complex I (NADH:ubiquinone oxidoreductase). NDUFV2, a nuclear-encoded complex I subunit gene, was also associated with bipolar disorder [12]. These results suggest that other genetic variations of complex I subunits in mtDNA are also risk factors for bipolar disorder.

Human mtDNA is inherited only maternally and encodes 13 protein subunits of the respiratory chain, including 7 complex I subunit genes, 22 tRNAs, and rRNAs [13]. It has been reported [14] that heteroplasmic tRNA mutations of mtDNA are related to neuromuscular diseases such as mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), and myoclonus epilepsy with ragged-red fibers. Large-scale deletions are related to CPEO. On the other hand, there are missense mutations of mtDNA related to diseases, such as neurogenic muscle weakness, ataxia, and retinitis pigmentosa; Leigh encephalopathy; and Leber hereditary optic neuropathy (LHON). Most are heteroplasmic, a mixture of mutant and wild-type mtDNA, but sometimes these mutations can be homoplasmic in patients. The homoplasmic mutation of 1555A→G in the rRNA coding region related to inherited hearing loss caused by aminoglycoside toxicity is well described [15,16]. Alterations in mtDNA have also been studied in patients with Parkinson disease and Alzheimer disease [17,18]. The phenotypes of mitochondrial diseases are diverse and overlapping. The same mtDNA mutation can produce quite different phenotypes, while different mutations can produce similar phenotypes. The mutations or polymorphisms associated with bipolar disorder, if any, may also cause overlapping phenotypes and become a risk factor for other disorders.

In this study, we hypothesized that there are some homoplasmic mutations or polymorphisms increasing the risk for bipolar disorder and other signs and symptoms related to mitochondrial impairment. To identify such nucleotide substitutions of mtDNA, we sequenced the entire 16.6-kb mtDNA of patients with comorbidity of bipolar disorder and somatic symptoms frequently associated with mitochondrial disorders. Among newly identified nonsynonymous nucleotide substitutions in these patients, the 3644T→C at NADH-ubiquinone dehydrogenase subunit I (ND1), decreasing mitochondrial membrane potential and complex I activity, was associated with bipolar disorder. The comorbidity with bipolar disorder was present in most of these cases but their phenotypes were various. It was suggested that this mutation could increase risks for bipolar disorder with syndromic comorbidity.

Results and discussion

Unreported homoplasmic mtDNA base substitutions in patients

We examined the entire mtDNA sequence of six patients with bipolar disorder and somatic symptoms suggestive of mitochondrial disorders, such as ptosis, optic neuropathy, cardiomyopathy, and myoclonus (Table 1). None of them could be diagnosed as known mitochondrial diseases, such as MELAS, CPEO, and LHON, because of the reasons as described under Case reports. Five of them had a family history of mood disorder compatible with maternal inheritance. Every patient had several base substitutions compared with the revised Cambridge Reference Sequence [13,19]. The average number of base substitutions in each individual was 32.5 ± 6.9 (mean ± SD), and that of nonsynonymous base substitutions was 5.5 ± 2.1. We consulted the MITOMAP database (http://www.mitomap.org/) [20,21], and two mutations were provisionally reported in relation to mitochondrial diseases, 11084A→G (MELAS) and 12311T→C (CPEO). We also found four nonsynonymous nucleotide substitutions, 3644T→C, 4705T→C, 13651A→G, and 13928G→T, which were not registered in the MITOMAP, all of which were in the complex I subunits. We confirmed that these base substitutions were homoplasmic by the PCR restriction-length polymorphism method (PCR-RFLP).

To identify the mtDNA base substitutions having pathophysiological significance, we examined whether these base substitutions were found in 96 Japanese centenarians using the mtSNP database (Human Mitochondrial Genome Polymorphism Database in Japan, http://www.giib.or.jp/mtsnp/index_e.html) [22]. We regarded the base substitutions found in centenarians as having minimum pathophysiological significance. Base substitutions 4705T→C, 11084A→G, 12311T→C, and 13651A→G were found in centenarians, while two base substitutions, 3364T→C and 13928G→T, were not found in centenarians.

Table 1
Patients and unreported nucleotide substitutions of mitochondria DNA

Case	Diagnosis	Gender	Age at onset	Clinical manifestations		MtDNA substitutions	
				Physical symptoms	Family history	Unreported	Provisionally disease related
1	Bipolar I disorder	F	17	Optic neuritis	Mo, depression	13651A→G	
2	Bipolar I disorder	M	30	Cerebral infarction Dilated cardiomyopathy	Bro, bipolar disorder MoSib, psychotic NOS		
3	Bipolar I disorder	M	50	Ptosis Epilepsy Cardiac arrhythmia	MoSib, depression		12311T→C (CPEO)
4	Bipolar I disorder	F	24	Epileptic EEG	Bro, bipolar disorder Sis, NOS		11084A→G (MELAS)
5	Bipolar I disorder	M	57	Ptosis Muscle weakness NIDDM Multiple cerebral infarction	Sporadic	3644T→C	
6	Bipolar I disorder	M	35	Ptosis	Sib, depression	4705T→C 13928G→T	

Abbreviations: Mo, mother; Bro, brother; Sis, sister; Sib, sibling; MoSib, mother's sibling; psychotic NOS, psychotic disorder not otherwise specified.

Association study of mtDNA base substitutions

To know whether these two base substitutions, 3644T→C and 13928G→T, are associated with bipolar disorder, we used two sets of the study subjects. The initial association study consisted of 199 patients with bipolar disorder and 258 healthy volunteers. An additional independent sample set in COSMO (Collaborative Study of Mood Disorder) consisted of 431 patients with bipolar disorder and 476 healthy volunteers, was also used. To examine whether there is a hidden population structure, we performed stratification analysis on the initial samples using eight polymorphisms [3] using the method of Pritchard et al. [23], and no subpopulation was found for either patients or controls. We performed a similar stratification analysis using 20 SNPs in 169 Japanese samples, including COSMO samples, and found no subpopulation. We further analyzed the stratification in 169 Japanese samples using 374 microsatellite markers and found no hidden subpopulation (Yamada et al., manuscript in preparation). Thus, we concluded that there is no hidden subpopulation in our Japanese samples. Six patients examined for the entire mtDNA sequence were included in the first sample set, because they developed comorbid somatic symptoms after the diagnosis of bipolar disorder.

We genotyped at 3644 and 13928 by PCR-RFLP in the initial sample set (Table 2). Base 3644C was found in 5 of 199 Japanese patients with bipolar disorder in the first sample set, including the proband (case 5 in Table 1, II-1 of family A in Fig. 1), but in none of the controls (p = 0.015) (Table 2). Among other 4 patients, 1 had non-insulin-dependent diabetes mellitus (NIDDM), 1 had headache, and 1 had tremor suggestive of neurological impairment. In their family members, only 5 of 25 members in the same maternal lineages, who were assumed to have the same genotype, 3644C, developed

Table 2
Association study using independent sample sets and haplogroups

Base at 3644:	All samples					Haplogroup D (5178A/10398G)				
	T		C		p value	T		C		p value
Initial sample set										
Patients	97.5%	(194)	2.5%	(5)		94.4%	(68)	5.6%	(4)	
Controls	100.0%	(258)	0.0%	(0)	0.015*	100.0%	(97)	0.0%	(0)	0.003*
Independent sample set										
Patients	99.1%	(427)	0.9%	(4)		98.3%	(171)	1.7%	(3)	
Controls	99.8%	(475)	0.2%	(1)	0.197	100.0%	(192)	0.0%	(0)	0.106
Total sample set										
Patients	98.6%	(621)	1.4%	(9)		97.2%	(239)	2.8%	(7)	
Controls	99.9%	(733)	0.1%	(1)	0.007*	100.0%	(289)	0.0%	(0)	0.004*

Each number in parentheses shows the real number of subjects. The p value was given by Fisher's exact test.
* Statistically significant.



Fig. 1. Pedigrees of the probands with bipolar disorder and mitochondrial 3644C mutation. Arrows indicate the probands with bipolar disorder. Closed squares and circles indicate the patients with bipolar disorder or other mental disorders as follows: D, I-2 had a psychotic disorder not otherwise specified, II-2 had schizotypal personality disorder. Their comorbidities were as follows: A, II-1 had muscle weakness, ptosis, and NIDDM (case 5 in Table 1); C, II-1, had essential tremor; D, II-1, had NIDDM; E, I-2, II-1, II-2, and III-1 had headache. To maintain the anonymity of the pedigrees, the sexes of the unaffected siblings are not shown.

bipolar disorder, of which 4 patients with 3644C had comorbid physical symptoms and one had only bipolar disorder. Mutation 3644T→C converts amino acid 113 valine in the putative third transmembrane region of ND1, the protein subunit of complex I, to alanine. This 113 valine is well conserved from *Drosophila* to 61 mammalian species. There was no difference in the frequency of 13928G→T [13 of 199 patients with bipolar disorder (6.5%) and 19 of 258 controls (7.4%), $p = 0.804$ by Fisher's exact test]. Mutation 13928G→T changes the 531 serine into isoleucine in the ND5 subunit and it was not conserved even among mammalian species.

We further analyzed 3644T→C as a candidate risk factor for bipolar disorder using the independent sample set obtained from COSMO. While 4 additional individuals having 3644C were found among the patients, only 1 of the 476 controls had 3644C. Although this difference in frequency was not statistically significant ($p = 0.197$), this is likely due to the low statistical power to detect the difference (0.29). In the analysis of total samples having higher statistical power (0.79), 3644C was significantly more common in bipolar disorder than in the controls ($p = 0.007$) (Table 2).

Since mtDNA is highly polymorphic, other polymorphisms possibly confounded the association analysis. To minimize the effects of other polymorphisms, we categorized these samples into mitochondrial DNA haplogroups and the association analysis was repeated in each haplogroup. Seven patients with 3644C were assigned to the Asian haplogroup D characterized by 5178A/10398G [22], which we reported as an anti-risk haplotype for bipolar disorder [10]. The 3644C was significantly associated with bipolar disorder in haplogroup D (Table 2). On the other hand, only 1 control subject and 2 patients with 3644C were classified into haplogroup M characterized by 5178C/10398G, and no association was found in haplogroup M [2 of 187 patients (1.1%) and 1 of 233 controls (0.4%), $p = 0.588$].

We concluded that 3644C was associated with bipolar disorder for the following reasons: 3644T→C was associated with bipolar disorder in the initial case-control study; this substitution converts well-conserved amino acid 113 valine to alanine in ND1. A similar trend was observed in the independent samples, although there was no significant difference, possibly due to the small number of subjects replicating the association. In the analysis of the total sample set having enough statistical power to detect a difference, 3644C was significantly associated with bipolar disorder. The significant association between 3644C and bipolar disorder remained in haplogroup-matched case-control analysis.

We called 3644C a "mutation," because its frequency was very low (0.14% in 734 controls and 0.7% in 1364 total samples examined), it converted a well-conserved amino acid, and it appeared in at least two independent haplogroups. However, this mutation is not sufficient to cause bipolar disorder because 3644C was found in 1 healthy volunteer, and only 5 of 25 members in the same maternal lineages, all of whom were assumed to have 3644C, developed bipolar disorder. Among these patients, comorbidity in 4 patients with bipolar disorder was heterogeneous: 2 had NIDDM, 1 headache, and 1 tremor suggestive of neurological impairment. The other patient had only bipolar disorder. It means that 3644C cannot be a risk factor for comorbid symptoms seen in these patients but could be a risk factor for bipolar disorder, if not a causative mutation. Bipolar disorder is a multigenic disease and one type of mutation in mtDNA can cause various phenotypes. We

postulate that synergistic effects of other risk factors and 3644C could cause bipolar disorder.

Functional analyses in cybrids with 3644C

To evaluate the functional consequences of 3644T→C, we generated cell lines of the transmitochondrial hybrids, "cybrids," using the platelets derived from the subjects. Different from heteroplasmic mutations in the regions of tRNAs and protein subunits, functional impairment associated with homoplasmic mutation has not been well established. In the case of heteroplasmic mutation, two cybrid cell lines with different nucleotides at one particular position of mtDNA could be generated and analyzed. On the other hand, in the case of homoplasmic mutation, it was impossible to identify such a pair of cell lines. To minimize the effects of other polymorphisms, we compared cybrids with 3644C with haplogroup-matched controls for functional studies. A total of 24 cybrid cell lines were obtained from the initial sample set, and 9 cybrid cell lines belonged to haplogroup D, 5178A/10398G (Table 3). Among the 9 cell lines, only 2 were from patients with 3644C (II-1 in family D and II-2 in family E, in Fig. 1) and 7 were from subjects with 3644T (3 patients with bipolar disorder and 4 controls). We could not obtain other samples with 3644C because of ethical reasons.

Mitochondrial membrane potential (MMP) was measured using JC-1, a fluorescent cationic dye, which accumulates in mitochondria and changes its emission from wavelength 527 nm (monomer) to 590 nm (aggregates) depending on the mitochondrial membrane potential, and a fluorescence-activated cell sorter (FACS), and it distinguished well the difference between control cybrids and $\rho^0$206 cells lacking mtDNA: while 82.9 ± 9.9% (mean ± SD, N = 12) of the cybrids from control subjects were polarized, only 13.2 ± 7.7 (mean ± SE of three measurements) of the $\rho^0$206 cells were polarized (Fig. 2, left and right, respectively). This indicated that our measurement method is sensitive enough to detect the difference in MMP. The percentage of polarized cells was significantly decreased in cybrids with 3644C [51.7 ± 6.6 and 67.0 ± 4.3% (means ± SE), respectively] compared with haplogroup-matched cybrids (df = 8, p = 0.04 by Mann-Whitney U test) (Table 3). There was no significant difference between cybrids of bipolar disorder and controls nor between cybrids of other haplogroups.

Subsequently, the activities of complexes I (rotenone-insensitive), III, and IV in the electron-transport chain were measured using the citrate synthase activity as the reference (Table 4). The activity of $\rho^0$206 cells was measured to assess nonspecific activity. The 3644C group consisted of two cybrid cell lines. While there was no significant difference between complex III and complex IV activities ($p > 0.1$), complex I activity of the two cybrids with 3644C tended to be lower than four haplogroup-matched control cybrids (df = 5, p = 0.06 by Mann-Whitney U test). Decreased MMP could be explained by reduced complex I activity since MMP is maintained by the efflux of protons from the mitochondrial matrix, in which complex I plays an important role. MMP generated by the proton gradient is the driving force of not only ATP synthesis but also Ca^{2+} uptake across the mitochondrial inner membrane. We hypothesized that impaired mitochondrial Ca^{2+} uptake caused altered calcium signaling in bipolar disorder. Our result of decreased MMP in cybrids with 3644C supports our hypothesis.

Interestingly, the mtSNP database [22] showed that while 3644C was not found in 96 centenarians, it was found in 3.1% (3/96) of patients with Alzheimer disease and 2.0% (2/96) of patients with Parkinson disease. These findings suggested a possibility that 3644C is a risk factor common to bipolar disorder and neurodegenerative disorders, rather than a causative mutation only for bipolar disorder. If 3644C is also a risk factor for neurodegener-

Table 3
Mitochondrial membrane potential (MMP) of 24 cybrid cell lines

	N	Age	(C/B)	Gender	MMP
Diagnosis					
Control	12	48.0 ± 9.2		6/6	82.9 ± 9.9
Bipolar disorder	12	41.8 ±11.4		6/6	77.2 ±11.0
Bipolar disorder with 3644T	10	40.7 ±12.0		5/5	80.8 ± 7.0
Bipolar disorder with 3644C	2	42, 53		1/1	59.4 ±10.9*
Haplogroup					
10398A–5178C–3644T	7	43.6 ± 10.6	4/3	3/4	81.9 ± 8.6
10398G–5178C–3644T	8	41.6 ± 10.7	4/4	4/4	80.8 ± 9.5
10398G–5178A–3644T	7	48.9 ± 10.5	4/3	3/4	83.3 ± 8.5
10398G–5178A–3644C	2	42, 53	0/2	1/1	59.4 ±10.9**
ρ^0 cells	1				13.21

C/B, numbers of control/bipolar disorder; gender, number of men/women. The p value was given by the Mann–Whitney U test.
* p = 0.03 vs 3644T, 0.08 vs controls.
** p = 0.04 vs 3644T, 0.03 vs all other haplogroups.



Fig. 2. Measurement of mitochondrial membrane potential using JC-1 and FACS. Vertical line, the fluorescence intensity of 590 nm, reflecting the aggregates and indicating high MMP. Horizontal line, the fluorescence intensity of 527 nm, reflecting the monomer and indicating low MMP. 10,000 cells were examined for one cell line. Representative results of one experiment each from three cell lines are shown. Left, control cybrids whose haplogroups were matched with the cybrids with 3644C; middle, cybrids with 3644C; right, $\rho^0$206 cells. While most control cybrids were polarized, having high 590/527 nm, most $\rho^0$206 cells were depolarized. The cybrids with 3644C were intermediate, having both polarized and depolarized cells.

ative disorders, the mechanism might be explained by a disruption of MMP that causes apoptosis. It is also compatible with the reduction of complex I activity in platelets or altered calcium signaling in cybrids derived from patients with Parkinson disease or Alzheimer disease [24–26]. Neuropathological studies of bipolar disorder also showed a decreased number of neurons in postmortem brains [27,28]. It was pointed out that having bipolar disorder increases the risk of Alzheimer disease [29,30] and Parkinson disease [31]. Two mood stabilizers, lithium and valproate, are known to have antiapoptotic effects by increasing Bcl-2 [32]. These findings are also compatible with the possibility that 3644C is a risk factor common to bipolar disorder and neurodegenerative disorders.

One might have a concern that 3644C is not a risk factor for bipolar disorder but associated with physical symptoms. Although the initial patient had several physical symptoms suggestive of mitochondrial disorder such as ptosis, muscle weakness, NIDDM, and cerebral infarction, other patients carrying 3644C had no or one nonspecific comorbid symptom. Thus, the apparent association between bipolar disorder and 3644C cannot be explained by the secondary phenomenon due to physical symptoms. However, it cannot be ruled out that these patients carrying 3644C have some subtle mitochondria-related symptoms that were not clinically apparent. In fact, there are reports of patients with pathogenic mtDNA mutations such as 3243A→G who showed psychotic symptoms at first and developed mitochondrial diseases later [33,34]. It might be possible that detailed physical examinations, for example, glucose tolerance test or close neurological examinations, would reveal subtle comorbid somatic symptoms. Needless to say, we need to address whether the 3664C substitution is associated with somatic symptoms alone. In the future, it is needed to look carefully at the phenotype and the clinical course of these subjects and investigate whether 3644C is associated with bipolar disorder or a bipolar disorder-somatic symptom subtype.

Functional impairment was reported also in the homoplasmic mutation, 1555A→G, in maternally inherited hearing loss [15,16]. The 11778A mutation of LHON, which is usually heteroplasmic but sometimes homoplasmic, was also shown to cause a modest reduction in complex I activity [35]. It was pointed out that the nuclear background potentially affects the expression of mtDNA polymorphisms [36]. Further study using cybrids with another nuclear background would be interesting. The mechanism of how the V113A amino acid substitution caused by 3644T→C in ND1 decreases complex I activity cannot be explained since the structure and function of each protein subunit are not yet well known. In particular, it remains unclear how complex I translocates protons across the mitochondrial inner membrane coupled to electron transfer. In summary, 3644T→C is a rare base substitution of mtDNA but induces modest impairment of complex I activity and becomes a risk factor for bipolar disorder.

Materials and methods

Subjects

Patients with bipolar disorder were diagnosed according to the DSM-III-R or DSM-IV criteria by at least two

Table 4
Enzyme activities of electron-transport chain of cybrids with 3644C and controls

	Control (mean ± SD), $N = 4$	3644C (mean ± SD), $N = 2$	ρ^0cells	p value*
Complex I/CS	14.47 ± 5.43	7.64 ± 0.08	4.82	0.06
Complex III/CS	32.15 ± 12.78	21.12 ± 2.72	7.36	0.36
Complex IV/CS	39.74 ± 11.24	29.21 ± 6.97	0.76	0.36

* The p value was calculated using the Mann–Whitney U test.

interview sessions by two senior psychiatrists and a consensus diagnosis was made. Their family history of mental disorder was assessed by interviewing the proband and available relatives. Control subjects were recruited from the staff or students of participating institutes and their friends, who reported themselves to be healthy. Written informed consent was obtained from all subjects. This study was approved by the ethics committees of RIKEN and all participating institutes.

The study subjects for the initial association study consisted of 199 patients with bipolar disorder (143 bipolar I and 56 bipolar II, 76 male and 123 female, 49.8 years of age on average) and 258 healthy volunteers (129 male and 129 female, 33.0 years of age on average). An additional independent sample set in COSMO consisted of 431 patients with bipolar disorder (214 male and 217 female, 49.5 years of age on average) and 476 healthy volunteers (226 male and 250 female, 50.4 years of age on average).

Six patients with bipolar disorder with somatic symptoms suggestive of mitochondrial disorders were chosen from the first sample set for examination of the entire mtDNA. They had been recruited in our bipolar disorder study based on our inclusion criteria, having DSM-IV bipolar disorder by consensus diagnoses after two nonstructured interview sessions with senior psychiatrists, and exclusion criteria, having no clinically remarkable neurological diseases, head trauma, or comorbid Axis II diagnoses. Characteristics of these six subjects are listed below and summarized in the Table 1.

The transmitochondrial cybrids for the following functional analyses were generated from 24 subjects in the initial samples, including two patients with 3644C.

Case reports

Case 1, 38-year-old female, is a patient with bipolar I disorder without psychotic features. She had the first episode of mania with psychomotor agitation and confusion at age 17. At age 27, she was admitted to a hospital due to bilateral optic neuritis. She had no other symptoms suggestive of multiple sclerosis. Her optic neuritis was improved by steroid therapy, and final diagnosis was idiopathic optic neuropathy. Because she had no relatives with optic neuropathy and her symptoms were reversible, Leber disease was not considered by the attendant ophthalmologist.

Case 2 is a 61-year-old male diagnosed as having bipolar I disorder. At age 30, he had the onset of mania with mood-incongruent psychotic features. At age 60, after being discharged from a psychiatric hospital, he was admitted to a hospital due to stroke. Brain imaging revealed infarctions in the cerebellum and the brain stem. During this hospitalization, chest X-ray showed enlarged heart and he was diagnosed as idiopathic dilated cardiomyopathy. He also had renal failure. His attendant physician did not suspect mitochondrial disease.

Case 3 is a 56-year-old male diagnosed with bipolar I disorder. At age 49, he had the onset of depression characterized by depressive mood, fatigability, retardation, insomnia, and suicidal thought. At age 52, he suddenly became manic. During this manic episode, he caused a motor vehicle accident. He was admitted to a psychiatric ward for the treatment of mania. After the first admission, he had generalized tonic clonic seizures. Although electroencephalography (EEG) recording showed no signs of epilepsy, he was clinically diagnosed as having epilepsy. At age 54, he complained of swollen eyelid, and medical examination did not show any signs of renal failure. He also complained of muscle weakness and had an episode of falling down due to muscle weakness. A neurologist saw this patient and assessed that ptosis may be present but fluctuating and was not pathological. He also showed some tendency of disturbed movement of the eyes, but it was also fluctuating and he did not have diplopia. Muscle weakness was not objectively present. Based on these clinical examinations, the neurologist ruled out mitochondrial disease from differential diagnosis and judged that further investigation was not necessary. Electrocardiogram indicated supraventricular extrasystole, but it was not clinically remarkable.

Case 4 is a 46-year-old female diagnosed with bipolar I disorder. At age 24, she had the onset of mania. At age 40, she began rapid cycling. During her psychiatric hospitalization, EEG recording showed epileptic abnormality. However, she did not have any signs or symptoms of epilepsy and was not diagnosed as epileptic.

Case 5 is 57-year-old male diagnosed as having bipolar I disorder. He had the onset of a manic episode at age 50. Since his clinical representation resembled confusion caused by organic mental disorder, he received lumbar puncture by a neurologist during psychiatric hospitalization, which showed elevated cerebrospinal fluid protein levels. The neurologist also noted muscle weakness and slight ptosis on the left eyelid. However, these symptoms were improved without any treatment and his subsequent manic episodes were typical manic syndrome without any additional neurological features or psychotic features. He was finally diagnosed as having bipolar I disorder. After the onset of bipolar disorder, he was diagnosed as having non-insulin-dependent diabetes mellitus. His cranial magnetic resonance image showed multiple subcortical silent infarction.

Case 6 is a 38-year-old male having bipolar I disorder. His clinical record was published elsewhere [37]. He complained of ptosis during antipsychotic treatment. Both a neurologist and an ophthalmologist examined and diagnosed him as not having any mitochondrial disease, since his sign was transient and not clinically remarkable.

MtDNA sequencing

Total DNA was extracted from peripheral blood leukocytes by standard protocols. Entire mtDNA sequenc-

ing was performed as previously described [38] with some modifications. In short, each DNA sample was diluted to 10 μg/ml, and nested PCR was performed. PCR was initially performed to obtain two long PCR products, 6 and 11 kb of mtDNA; the second PCR was designed as a set of three overlapping fragments from the first 6-kb PCR product and six fragments from the first 11-kb PCR product. After the second PCR, the products were treated with a SeqDirect PCR Cleaning kit (Qbiogene, Carlsbad, CA, USA) according to the manufacturer's protocol. Both strands of these fragments were then sequenced with the BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA) and ABI Prism 3700 DNA sequencer (Applied Biosystems). Each mtDNA site was read at least three times, including at least once for each strand.

Genotyping

The two base substitutions of mtDNA, 3644T→C and 13928G→T, were genotyped using the PCR-RFLP method and sequencing. The enzymes and experimental conditions for the PCR-RFLP were as follows: 3644 was genotyped by primers 5′-GTAGAATGATGGCTAGGGTGACT-3′ and 5′-TCTAGCCACCTCTAGCCTAGACG-3′ and the restriction enzyme *Tai*I (Fermentas), 13928 by 5′-CATACTCGGATTCTACGCTA-3′, 5′-TTTAGGTAATAGCTTTTCTA-3′, and *Nhe*I (Takara Bio, Inc., Shiga, Japan). MtDNAs 5178C→A and 10398A→G were genotyped to determine the haplogroups. Genotypes of 5178C→A and 10398A→G were examined as previously described [10].

Generation of cybrids

The 143B.TK$^-$ $\rho^0$206 cell line, lacking mtDNA and established by King and Attardi [39], was used for generating cybrids. Platelets of patients and controls were separated from peripheral blood and fused with $\rho^0$206 cells using 40% polyethylene glycol 1500 (Sigma), as previously described [40]. We used DMEM (Gibco BRL) containing 10% FBS (fetal bovine serum; Gibco BRL), penicillin/streptomycin, pyruvate (Gibco BRL), and uridine (Sigma) as the growth medium for ρ^0 cells. For the selection of transmitochondrial cybrid cell lines, we used DMEM containing 10% dialyzed FBS, penicillin/streptomycin, and pyruvate. After the harvest of individual cybrid cell lines, the integration of mtDNA was confirmed by Southern blot analysis using 18S ribosomal RNA repeating units as a reference [41]. The identity of the mtDNA of the cybrids with that of the donor was verified by sequencing the D loop and genotyping several polymorphisms. For Southern blot analysis, we used the ECL Labeling and Detection System according to the manufacturer's protocol (Amersham Biosciences Corp., NJ, USA). Cybrids were stored in liquid nitrogen for further experiments.

Measurement of MMP using JC-1

MMP was estimated using JC-1 (Molecular Probes, Eugene, OR) and flow cytometry. Cybrids stored in liquid nitrogen were thawed and incubated in an atmosphere of 5% CO_2 at 37°C in DMEM containing 10% FBS, penicillin/streptomycin, and pyruvate. Cells (1×10^6) were trypsinized and harvested in 10 ml of DMEM containing 10% FBS, washed with PBS (phosphate-buffered saline) once, and stained with DMEM containing 5 μg/ml JC-1 for 15 min at 37°C. Cells were then washed with PBS and subjected to analysis using a FACS (Epics Elite cell sorter; Beckman Coulter, Fullerton, CA, USA) as previously described [42]. The excitation wavelength was 488 nm by argon ion laser. Emissions at 590 and 527 nm were isolated by each photomultiplier detector and 10,000 cells were measured for each experiment. The experiment was performed in triplicate for each cell line. The cells with polarized mitochondria were defined by an intensity ratio of 590 nm/527 nm above 0.2.

Activities of enzymes in the electron-transport chain

For the sample preparation of the mitochondrial fraction, each line of cybrids was amplified until the cell count was 5×10^7. Cybrids were trypsinized and harvested in DMEM. After being washed once with PBS and once with isolation buffer [210 mM D-mannitol, 71 mM sucrose, 1 mM EGTA, 0.5% bovine serum albumin (fatty acid free), 5 mM Hepes, pH 7.2], the cells were suspended in 5 ml of isolation buffer. Using a chilled Dounce glass homogenizer with a loose fitting pestle, 20 passes were applied to the cell suspension on ice, which was centrifuged at 700*g* for 7 min at 4°C. The supernatant was centrifuged at 10,000*g* for 7 min at 4°C, and the mitochondrial pellet was obtained. The pellet was suspended in 250 mM sucrose, divided into aliquots, and kept at −80°C until use. Activities of complexes I, III, and IV were measured as previously described [43]. Rotenone-sensitive complex I activity was measured by the change in absorption of decylubiquinone. All samples were measured within 1 month from preparation. The activity of each complex was corrected by citrate synthase activity. All the chemical products for these assays were obtained from Sigma. We used a UVmini1240 spectrophotometer (Shimadzu, Kyoto, Japan) for this experiment.

Acknowledgments

We thank all the volunteers who participated in this study. We express our thanks to the members of the Research Resource Center at the RIKEN Brain Science Institute, especially to Mr. Miyazaki for the sequence procedure and to Mr. Ohtawa for the analysis of mitochondrial membrane potential. The 143B.TK$^-$ $\rho^0$206 cell line was a gift from Dr. Giuseppe Attardi to Dr. Makoto Yoneda.

References

[1] P. Sklar, S.B. Gabriel, M.G. McInnis, P. Bennett, Y.M. Lim, G. Tsan, S. Schaffner, G. Kirov, I. Jones, M. Owen, et al., Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neurotrophic factor, Mol. Psychiatry 7 (2002) 579–593.

[2] M. Neves-Pereira, E. Mundo, P. Muglia, N. King, F. Macciardi, J.L. Kennedy, The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study, Am. J. Hum. Genet. 71 (2002) 651–655.

[3] C. Kakiuchi, K. Iwamoto, M. Ishiwata, M. Bundo, T. Kasahara, I. Kusumi, T. Tsujita, Y. Okazaki, S. Nanko, H. Kunugi, et al., Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder, Nat. Genet. 35 (2003) 171–175.

[4] T. Kato, S. Takahashi, T. Shioiri, T. Inubushi, Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo ^{31}P and ^{7}Li magnetic resonance spectroscopy, J. Affect. Disord. 27 (1993) 53–59.

[5] C. Konradi, M. Eaton, M.L. MacDonald, J. Walsh, F.M. Benes, S. Heckers, Molecular evidence for mitochondrial dysfunction in bipolar disorder, Arch. Gen. Psychiatry 61 (2004) 300–308.

[6] G. Siciliano, A. Tessa, S. Petrini, M. Mancuso, C. Bruno, G.S. Grieco, A. Malandrini, L. DeFlorio, B. Martini, A. Federico, et al., Autosomal dominant external ophthalmoplegia and bipolar affective disorder associated with a mutation in the ANT1 gene, Neuromuscul. Disord. 13 (2003) 162–165.

[7] J.N. Spelbrink, F.Y. Li, V. Tiranti, K. Nikali, Q.P. Yuan, M. Tariq, S. Wanrooij, N. Garrido, G. Comi, L. Morandi, et al., Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria, Nat. Genet. 28 (2001) 223–231.

[8] G. Van Goethem, B. Dermaut, A. Lofgren, J.J. Martin, C. Van Broeckhoven, Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions, Nat. Genet. 28 (2001) 211–212.

[9] F.J. McMahon, O.C. Stine, D.A. Meyers, S.G. Simpson, J.R. DePaulo, Patterns of maternal transmission in bipolar affective disorder, Am. J. Hum. Genet. 56 (1995) 1277–1286.

[10] T. Kato, H. Kunugi, S. Nanko, N. Kato, Mitochondrial DNA polymorphisms in bipolar disorder, J. Affect. Disord. 62 (2001) 151–164.

[11] F.J. McMahon, Y.S. Chen, S. Patel, J. Kokoszka, M.D. Brown, A. Torroni, J.R. DePaulo, D.C. Wallace, Mitochondrial DNA sequence diversity in bipolar affective disorder, Am. J. Psychiatry 157 (2000) 1058–1064.

[12] S. Washizuka, C. Kakiuchi, K. Mori, H. Kunugi, O. Tajima, T. Akiyama, S. Nanko, T. Kato, Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder, Am. J. Med. Genet. 120B (2003) 72–78.

[13] S. Anderson, A.T. Bankier, B.G. Barrell, M.H. de Bruijn, A.R. Coulson, J. Drouin, I.C. Eperon, D.P. Nierlich, B.A. Roe, F. Sanger, et al., Sequence and organization of the human mitochondrial genome, Nature 290 (1981) 457–465.

[14] D.C. Wallace, Mitochondrial diseases in man and mouse, Science 283 (1999) 1482–1488.

[15] T.R. Prezant, J.V. Agapian, M.C. Bohlman, X. Bu, S. Oztas, W.Q. Qiu, K.S. Arnos, G.A. Cortopassi, L. Jaber, J.I. Rotter, et al., Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness, Nat. Genet. 4 (1993) 289–294.

[16] M.X. Guan, N. Fischel-Ghodsian, G. Attardi, Biochemical evidence for nuclear gene involvement in phenotype of non-syndromic deafness associated with mitochondrial 12S rRNA mutation, Hum. Mol. Genet. 5 (1996) 963–971.

[17] S.W. Chang, D. Zhang, H.D. Chung, H.P. Zassenhaus, The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain, Biochem. Biophys. Res. Commun. 273 (2000) 203–208.

[18] J.M. van der Walt, K.K. Nicodemus, E.R. Martin, W.K. Scott, M.A. Nance, R.L. Watts, J.P. Hubble, J.L. Haines, W.C. Koller, K. Lyons, et al., Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease, Am. J. Hum. Genet. 72 (2003) 804–811.

[19] R.M. Andrews, I. Kubacka, P.F. Chinnery, R.N. Lightowlers, D.M. Turnbull, N. Howell, Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA, Nat. Genet. 23 (1999) 147.

[20] A.M. Kogelnik, M.T. Lott, M.D. Brown, S.B. Navathe, D.C. Wallace, MITOMAP: a human mitochondrial genome database, Nucleic Acids Res. 24 (1996) 177–179.

[21] A.M. Kogelnik, M.T. Lott, M.D. Brown, S.B. Navathe, D.C. Wallace, MITOMAP: a human mitochondrial genome database—1998 update, Nucleic Acids Res. 26 (1998) 112–115.

[22] M. Tanaka, T. Takeyasu, N. Fuku, G. Li-Jun, M. Kurata, Mitochondrial genome single nucleotide polymorphisms and their phenotypes in the Japanese, Ann. N. Y. Acad. Sci. 1011 (2004) 1–20.

[23] J.K. Pritchard, M. Stephens, P. Donnelly, Inference of population structure using multilocus genotype data, Genetics 155 (2000) 945–959.

[24] Y. Aomi, C.S. Chen, K. Nakada, S. Ito, K. Isobe, H. Murakami, S.Y. Kuno, M. Tawata, R. Matsuoka, H. Mizusawa, J.-I. Hayashi, Cytoplasmic transfer of platelet mtDNA from elderly patients with Parkinson's disease to mtDNA-less HeLa cells restores complete mitochondrial respiratory function, Biochem. Biophys. Res. Commun. 280 (2001) 265–273.

[25] R.H. Swerdlow, J.K. Parks, J.N. Davis II, D.S. Cassarino, P.A. Trimmer, L.J. Currie, J. Dougherty, W.S. Bridges, J.P. Bennett Jr., G.F. Wooten, W.D. Parker, Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family, Ann. Neurol. 44 (1998) 873–881.

[26] J.P. Sheehan, R.H. Swerdlow, S.W. Miller, R.E. Davis, J.K. Parks, W.D. Parker, J.B. Tuttle, Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease, J. Neurosci. 17 (1997) 4612–4622.

[27] M.P. Vawter, W.J. Freed, J.E. Kleinman, Neuropathology of bipolar disorder, Biol. Psychiatry 48 (2000) 486–504.

[28] G. Rajkowska, Cell pathology in bipolar disorder, Bipolar Disord. 4 (2002) 105–116.

[29] L.V. Kessing, E.W. Olsen, P.B. Mortensen, P.K. Andersen, Dementia in affective disorder: a case-register study, Acta Psychiatr. Scand. 100 (1999) 176–185.

[30] R.C. Green, L.A. Cupples, A. Kurz, S. Auerbach, R. Go, D. Sadovnick, R. Duara, W.A. Kukull, H. Chui, T. Edeki, et al., Depression as a risk factor for Alzheimer disease: the MIRAGE Study, Arch. Neurol. 60 (2003) 753–759.

[31] F.M. Nilsson, L.V. Kessing, T.G. Bolwig, Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study, Acta Psychiatr. Scand. 104 (2001) 380–386.

[32] G. Chen, W.Z. Zeng, P.X. Yuan, L.D. Huang, Y.M. Jiang, Z.H. Zhao, H.K. Manji, The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS, J. Neurochem. 72 (1999) 879–882.

[33] E.C. Thomeer, W.M. Verhoeven, C.J. van de Vlasakker, J.L. Klompenhouwer, Psychiatric symptoms in MELAS: a case report, J. Neurol. Neurosurg. Psychiatry 64 (1998) 692–693.

[34] M. Yamazaki, H. Igarashi, M. Hamamoto, T. Miyazaki, I. Nonaka, A case of mitochondrial encephalomyopathy with schizophrenic psychosis, dementia and neuroleptic malignant syndrome, Rinsho Shinkeigaku 31 (1991) 1219–1223.

[35] M.D. Brown, I.A. Trounce, A.S. Jun, J.C. Allen, D.C. Wallace, Functional analysis of lymphoblast and cybrid mitochondria containing the 3460, 11778, or 14484 Leber's hereditary optic neuropathy mitochondrial DNA mutation, J. Biol. Chem. 275 (2000) 39831–39836.

[36] P.L. Roubertoux, F. Sluyter, M. Carlier, B. Marcet, F. Maarouf-Veray, C. Cherif, C. Marican, P. Arrechi, F. Godin, M. Jamon, et al., Mitochondrial DNA modifies cognition in interaction with the nuclear genome and age in mice, Nat. Genet. 35 (2003) 65–69.
[37] T. Kato, Y. Takahashi, Deletion of leukocyte mitochondrial DNA in bipolar disorder, J. Affect. Disord. 37 (1996) 67–73.
[38] J. Akanuma, K. Muraki, H. Komaki, I. Nonaka, Y. Goto, Two pathogenic point mutations exist in the authentic mitochondrial genome, not in the nuclear pseudogene, J. Hum. Genet. 45 (2000) 337–341.
[39] M.P. King, G. Attardi, Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation, Science 246 (1989) 500–503.
[40] A. Chomyn, S.T. Lai, R. Shakeley, N. Bresolin, G. Scarlato, G. Attardi, Platelet-mediated transformation of mtDNA-less human cells: analysis of phenotypic variability among clones from normal individuals—and complementation behavior of the tRNALys mutation causing myoclonic epilepsy and ragged red fibers, Am. J. Hum. Genet. 54 (1994) 966–974.
[41] I. Nishino, O. Kobayashi, Y. Goto, M. Kurihara, K. Kumagai, T. Fujita, K. Hashimoto, S. Horai, I. Nonaka, A new congenital muscular dystrophy with mitochondrial structural abnormalities, Muscle Nerve 21 (1998) 40–47.
[42] A. Sawa, G.W. Wiegand, J. Cooper, R.L. Margolis, A.H. Sharp, J.F. Lawler Jr., J.T. Greenamyre, S.H. Snyder, C.A. Ross, Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization, Nat. Med. 5 (1999) 1194–1198.
[43] I.A. Trounce, Y.L. Kim, A.S. Jun, D.C. Wallace, Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines, Methods Enzymol. 264 (1996) 484–509.

Association of Mitochondrial Complex I Subunit Gene *NDUFV2* at 18p11 with Bipolar Disorder in Japanese and the National Institute of Mental Health Pedigrees

Shinsuke Washizuka, Kazuya Iwamoto, An-a Kazuno, Chihiro Kakiuchi, Kanako Mori, Mizue Kametani, Kazuo Yamada, Hiroshi Kunugi, Osamu Tajima, Tsuyoshi Akiyama, Shinichiro Nanko, Takeo Yoshikawa, and Tadafumi Kato

Background: *Linkage with 18p11 is one of the replicated findings in molecular genetics of bipolar disorder. Because mitochondrial dysfunction has been suggested in bipolar disorder,* NDUFV2 *at 18p11, encoding a subunit of the complex I, reduced nicotinamide adenine dinucleotide (NADH) ubiquinone oxidoreductase, is a candidate gene for this disorder. We previously reported that a polymorphism in the upstream region of* NDUFV2, *−602G> A, was associated with bipolar disorder in Japanese subjects; however, functional significance of −602G> A was not known.*

Methods: *We screened the further upstream region of* NDUFV2. *We performed a case–control study in Japanese patients with bipolar disorder and control subjects and a transmission disequilibrium test in 104 parent and proband trios of the National Institute of Mental Health (NIMH) Genetics Initiative pedigrees. We also performed the promoter assay to examine functional consequence of the −602G> A polymorphism.*

Results: *The −602G> A polymorphism was found to alter the promoter activity. We found that the other haplotype block surrounding −3542G> A was associated with bipolar disorder. The association of the haplotypes consisting of −602G> A and −3542G> A polymorphisms with bipolar disorder was seen both in Japanese case–control samples and NIMH trios.*

Conclusion: *Together these findings indicate that the polymorphisms in the promoter region of* NDUFV2 *are a genetic risk factor for bipolar disorder by affecting promoter activity.*

Key Words: Bipolar disorder, haplotype, mitochondria, NADH ubiquinone oxidoreductase, promoter assay, transmission disequilibrium test

The etiology of bipolar disorder (BD) is still unknown, but family, twin, and adoption studies strongly suggest the involvement of genetic risk factors (Goodwin and Jamison 1990). Linkage studies have revealed a number of loci to be linked with BD. Of those, several investigators confirmed 18p11 as one susceptibility loci for BD (Berrettini et al 1997; Gershon et al 1996; Nothen et al 1999; Stine et al 1995; Turecki et al 1999). Nominally significant linkage of BD with chromosome 18 was also found in a recent extensive meta-analysis (Segurado et al 2003). Thus, 18p is one of the targets of the genetic association study of BD.

We have proposed a mitochondrial dysfunction hypothesis of BD (Kato and Kato 2000) on the basis of the following evidence: altered brain energy metabolism in patients with BD detected by phosphorus-31 magnetic resonance spectroscopy (Kato et al 1993), increased ratio of the mitochondrial DNA (mtDNA) deletion in the brains of patients with BD (Kato et al 1997), association with mtDNA polymorphisms causing amino acid substitutions in the subunits of complex I (reduced nicotinamide adenine dinucleotide [NADH]: ubiquinone oxidoreductase; Kato et al 2001).

From the Laboratories for Molecular Dynamics of Mental Disorders (SW, KI, AK, CK, KM, MK, TK) and Molecular Psychiatry (KY, TY), Brain Science Institute, RIKEN, Wako, Saitama; Department of Mental Disorder Research (HK), National Institute of Neuroscience; Kyorin University School of Health Sciences (OT); Department of Neuropsychiatry (TA), NTT East Kanto Medical Center; and Department of Psychiatry and Genome Research Center (SN), Teikyo University School of Medicine, Tokyo, Japan.

Address reprint requests to Tadafumi Kato, M.D., Ph.D., Laboratory for Molecular Dynamics of Mental Disorders, Brain Science Institute, RIKEN, Hirosawa 2-1, Wako, Saitama, 351-0198, Japan; E-mail: kato@brain.riken.go.jp.

Received March 9, 2004; revised June 22, 2004; accepted July 5, 2004.

0006-3223/04/$30.00
doi:10.1016/j.biopsych.2004.07.004

Complex I catalyzes the transfer of electrons from NADH to ubiquinone and the largest and most complicated enzyme in the mitochondrial electron transport chain, consisting of at least 43 subunits. Whereas seven subunits of complex I are coded in the mtDNA, the others are coded in the nuclear genome (Smeitink et al 2001). Of those, *NDUFV2* is located at 18p11 (de Coo et al 1995; Hattori et al 1995) and is a candidate gene for BD. Recently, Nakatani et al (2004) examined the gene expression patterns in the frontal cortex and hippocampus in animal models of depression and reported that *NDUFV2* was one of two genes altered in both regions. Moreover, Karry et al (2004) reported that protein levels of 24kDa subunit of complex I encoded by *NDUFV2* were altered in the autopsied brains of BD patients. These findings suggested a possible role of *NDUFV2* in mood disorders.

We previously screened mutations and polymorphisms in all exons and the 1-kb upstream region of *NDUFV2* in BD patients and reported that a polymorphism, −602G> A, in the upstream region was significantly associated with BD in Japanese (Washizuka et al 2003). The mRNA expression of *NDUFV2* was also significantly decreased in the lymphoblastoid cells of patients with bipolar I disorder.

In this study, we further screened the 4kb-upstream region of the *NDUFV2* and examined the association with BD in a Japanese case–control samples. Furthermore, we performed a promoter assay to examine the functional significance of the −602G> A polymorphism, which determines the major haplotypes associated with BD. We then examined whether a similar association was found in the National Institute of Mental Health (NIMH) Initiative Genetics Bipolar Pedigrees by the haplotype transmission disequilibrium test (TDT).

Methods and Materials

Japanese Case–Control Samples

The subjects with BD were 189 unrelated patients (117 women and 72 men, 136 with bipolar I disorder (BDI) and 53

BIOL PSYCHIATRY 2004;56:483–489
© 2004 Society of Biological Psychiatry

with bipolar II disorder (BDII; 49.8 ± 13.8 years) who were followed at the hospitals or clinics participating in this study. Their age at onset was 34.9 ± 13.4 years. Consensus diagnosis by at least two senior psychiatrists according to the DSM-IV criteria was made for each patient using a nonstructured interview and by reviewing medical records. The 222 unrelated control subjects (117 women and 105 men, 30.2 ± 8.3 years old) were recruited from hospital staff and students. Control subjects were not assessed for psychiatric symptoms by any structured interview method, but they showed good social functioning and reported themselves to be in good health. All the subjects were Japanese with characteristics as described previously (Washizuka et al 2003). The objective of this study was clearly explained, and written informed consent was obtained from all subjects.

Genomic DNA was extracted from leukocytes using standard methods. There was no evidence for the presence of population substructure in either control subjects or BD using the method of Prichard (2000; Kakiuchi et al 2003). The ethics committees of the Brain Science Institute and participating institutes approved this study.

NIMH Genetics Initiative Pedigrees

For TDT, 105 trio samples (94 trios with BDI probands and 11 trios with BDII probands) were obtained from NIMH Genetics Initiative Bipolar Pedigrees. Each trio was obtained from a larger NIMH family independent of each other. Of those, results of genotyping were inconsistent with the parent–child relationship in one pedigree with BDI. Thus, this pedigree was omitted from the analysis.

Mutation Screening of the *NDUFV2* Gene by Sequencing

Polymorphisms of the upstream region of the *NDUFV2* (GenBank accession number NT_010859) were screened in 20 randomly selected Japanese subjects (9 BDI, 3 BDII, and 8 control subjects). For the scanning of the 5′- upstream region, the following primer sets were used: 5′-TATAGGTCATGAACTCAAAAAGACG and 5′-GCCACACTGTTCACCTTCC. These primers amplified a 3983bp product. Polymerase chain reaction (PCR) was performed in a 25-μL volume containing 20 ng of genomic DNA, .2 μmol/L of each primer, 100 μmol/L of each dNTP, 12.5 μL of 2 × GC buffer I (Takara, Shiga, Japan), and 1.25 units of LA-Taq DNA polymerase (Takara). After an initial denaturation at 95°C for 2 min, 27 cycles consisting of 30 sec at 94°C, 30 sec at 62°C, and 4 min at 72°C were performed. An extension at 72°C for 5 min followed. Sequencing of the PCR products was conducted using the BigDye terminator sequencing kit (Applied Biosystems, Foster City, California) and an ABI 3700 DNA sequencer (Applied Biosystems). For this analysis, 15 sequence primers were used.

Genotyping

Five single nucleotide polymorphisms (SNPs) detected in the screening analysis, −3542G> A, −3245*T*> C, −3041*T*> G, −2694A> G, and −1020G> T, were genotyped in Japanese samples and NIMH bipolar pedigrees. For genotyping of the former four polymorphisms, genomic DNA was amplified by using the upstream primer 5′-AAACTAGCCCTTCCATTCTCCTT and the downstream primer 5′-CCTTCTTGTCTCATTGGCTTACA. These primers amplified a 1547bp product. We performed PCR in a 15-μL volume containing 15 ng of genomic DNA, .1 μmol/L of each primer, 25 μmol/L of each dNTP, 1.5 μL of 10 × Ex-Taq buffer (Takara), and .72 units of Ex-Taq DNA polymerase (Takara). After an initial denaturation at 95°C for 2 min, 35 cycles

Table 1. Pairwise Linkage Disequilibrium Between Polymorphisms in the *NDUFV2*

	Frequency of minor allele	−3542G>A	−3245T>C	−3041T>G	−2694A>G	−1020G>T	−796C>G	−795T>G	−602G>A	−233T>C	86C>T
−3542G>A	.32		r^2 = .97	r^2 = .17	r^2 = .97	r^2 = .10	r^2 = .33	r^2 = .33	r^2 = .91	r^2 = .20	r^2 = .59
−3245T>C	.32	D' = 1.00		r^2 = .16	r^2 = 1.00	r^2 = .10	r^2 = .29	r^2 = .29	r^2 = .63	r^2 = .16	r^2 = .59
−3041T>G	.28	D' = 1.00	D' = .93		r^2 = .17	r^2 = .06	r^2 = .23	r^2 = .23	r^2 = .11	r^2 = .08	r^2 = .21
−2694A>G	.32	D' = .98	D' = 1.00	D' = 1.00		r^2 = .11	r^2 = .34	r^2 = .34	r^2 = .97	r^2 = .21	r^2 = .60
−1020G>T	.16	D' = 1.00	D' = 1.00	D' = 1.00	D' = 1.00		r^2 = .29	r^2 = .29	r^2 = .09	r^2 = .04	r^2 < .01
−796C>G	.41	D' = .95	D' = .96	D' = .94	D' = .97	D' = 1.00		r^2 = 1.00	r^2 = .21	r^2 = .43	r^2 = .16
−795T>G	.41	D' = .95	D' = .96	D' = .94	D' = .97	D' = 1.00	D' = 1.00		r^2 = .21	r^2 = .43	r^2 = .16
−602G>A	.32	D' = .96	D' = .81	D' = .77	D' = .98	D' = .92	D' = .78	D' = .78		r^2 = .13	r^2 = .56
−233T>C	.28	D' = .96	D' = .84	D' = .65	D' = 1.00	D' = .29	D' = .86	D' = .86	D' = .83		r^2 = .27
86C>T	.39	D' = .86	D' = .87	D' = 1.00	D' = .87	D' < .01	D' = .59	D' = .59	D' = .83	D' = 1.00	

Table 2. Genotypic and Allele Distributions of the Additional *NDUFV2* Gene Polymorphisms and −602G>A in Japanese Controls and Bipolar Patients

Polymorphisms		Subject Counts (%)				
		Controls	BP Total	BPI	BPII	p Value[b]
−3542G>A						
Genotype	G/G	15 (.07)	25 (.13)	13 (.09)	12 (.23)	
	G/A	102 (.46)	80 (.42)	63 (.46)	17 (.32)	.02
	A/A	104 (.47)	85 (.45)	61 (.45)	24 (.45)	
P Value			.09	.62	.003	
Allele	G	132 (.30)	130 (.34)	89 (.32)	41 (.39)	.21
	A	310 (.70)	250 (.66)	185 (.68)	65 (.61)	
P Value			.20	.50	.08	
−3245T>C						
Genotype	T/T	15 (.07)	24 (.13)	12 (.09)	12 (.23)	
	T/C	101 (.47)	80 (.42)	64 (.47)	16 (.30)	.01
	C/C	97 (.46)	84 (.45)	59 (.44)	25 (.47)	
P Value			.14	.80	.002	
Allele	T	131 (.31)	128 (.34)	88 (.33)	40 (.38)	.38
	C	295 (.69)	248 (.66)	182 (.67)	66 (.62)	
P Value			.32	.61	.20	
−3041T>G						
Genotype	T/T	106 (.49)	98 (.52)	73 (.54)	25 (.47)	
	T/G	88 (.40)	86 (.46)	60 (.44)	26 (.49)	.009
	G/G	23 (.11)	4 (.02)	2 (.02)	2 (.04)	
P Value			.001	.002	.23	
Allele	T	300 (.69)	282 (.75)	206 (.76)	76 (.72)	.12
	G	134 (.31)	94 (.25)	64 (.24)	30 (.28)	
P Value			.07	.04	.63	
−2694A>G						
Genotype	A/A	16 (.07)	24 (.13)	12 (.09)	12 (.23)	
	A/G	99 (.46)	79 (.42)	62 (.46)	17 (.32)	.03
	G/G	100 (.47)	84 (.45)	60 (.45)	24 (.45)	
P Value			.19	.86	.006	
Allele	A	131 (.31)	128 (.34)	88 (.33)	40 (.38)	.38
	G	295 (.69)	248 (.66)	182 (.67)	66 (.62)	
P Value			.32	.61	.20	
−1020G>T						
Genotype	G/G	160 (.72)	131 (.69)	93 (.66)	38 (.72)	
	G/T	58 (.26)	52 (.28)	39 (.29)	13 (.25)	.77
	T/T	4 (.02)	6 (.03)	4 (.03)	2 (.03)	
P Value			.64	.62	.60	
Allele	G	378 (.85)	314 (.83)	225 (.83)	89 (.84)	.66
	T	66 (.15)	64 (.17)	47 (.17)	17 (.16)	
P Value			.44	.39	.76	
−602G>A[a]						
Genotype	G/G	17 (.08)	27 (.14)	15 (.11)	12 (.23)	
	G/A	106 (.48)	77 (.41)	60 (.44)	17 (.32)	.02
	A/A	99 (.44)	85 (.45)	61 (.45)	24 (.45)	
P Value			.07	.51	.003	
Allele	G	140 (.32)	131 (.35)	90 (.33)	41 (.39)	.37
	A	304 (.68)	247 (.65)	182 (.67)	65 (.61)	
P Value			.34	.66	.15	

BP, bipolar disorder
[a]Data of Washizuka et al (2003).
[b]Differences in genotype distributions or allele frequencies among patients with BPI, BPII, and controls.

consisting of 30 sec at 94°C, 30 sec at 61°C, and 2 min at 72°C were performed. An extension at 72°C for 3 min followed.

For genotyping of the −1020G> T polymorphism, the primer sets were used as follows: 5′-ACCAAGGCATTTGGTATCTATTCT and 5′-ATGTTTGTTTGGTTATCTCTGGAAA. We performed PCR in a 25-μL volume containing 25 ng of genomic DNA, .1 μmol/L of each primer, 25 μmol/L of each dNTP, 2.5 μL of 10 × Ex-Taq buffer, and 1.2 units of Ex-Taq DNA polymerase. After an initial denaturation at 95°C for 2 min, 35 cycles consisting of 20 sec at 94°C, 30 sec at 60°C, and 30 sec at 72°C were performed. An extension at 72°C for 3 min followed.

In addition, our previously reported polymorphisms of the *NDUFV2* gene (−796C> G, −795T> G, −602G> A, −233T> C, and 86C> T) were also genotyped in NIMH samples. The primer set and the PCR condition that were used in genotyping of these SNPs are shown in our previous article (Washizuka et al 2003).



Figure 1. Haplotype associations in Japanese case control samples: **(a)** three-marker haplotype analysis; **(b)** two-marker haplotype analysis. *P* value indicates the global *P* analyzed using COCAPHASE program. Gray squares indicate statistically significant global *p* value.



Figure 2. Promoter assay. Promoter activity of three kinds of reporter plasmids, having −602G or −602A and lacking the −602G> A site, were examined by the luciferase assay. Two kinds of cells, Hela-S3 and HEK293, were used. Four independent experiments were performed for each condition, and the mean and SEM values were presented. The transcription activity of the −602G construct was significantly higher than that of the −602A in both Hela-S3 and HEK293. The short construct lacking in the −602G> A site presented nearly equal activity of the −602A construct and had significantly smaller activity compared with −602G constructs. ** $p < .01$. * $p < .05$. + $p = .05$.

Sequencing of the PCR products was conducted using the BigDye terminator sequencing kit (Applied Biosystems) and an ABI 3700 DNA sequencer (Applied Biosystems).

Statistical Procedures

Deviations from Hardy–Weinberg equilibrium (HWE) were evaluated by use of the Arlequin program (http://anthropologie.Unige.Ch/arlequin/methods.html). Genotype distributions and allele frequencies between patients and control subjects were computed using Fisher's Exact Probability Test, which was applied using SPSS software (SPSS, Tokyo, Japan). For other analyses, UNPHASED programs (COCAPHASE and TDTPHASE; http://www.rfcgr.mrc.ac.uk/~fdudbrid/software/unphased/) were used. The normalized LD coefficient D' and the squared correlation coefficient r^2 were calculated using COCAPHASE program. For TDT of NIMH trio samples, the McNemar Test was used. For the computation of haplotype frequencies, evaluation of haplotypic distributions, and TDT analysis of the multimarker haplotypes, the COCAPHASE and TDTPHASE programs were used. To evaluate the data appropriately, we reanalyzed the significant result using the permutation test implemented in COCAPHASE and TDTPHASE. Sequences were searched for potential transcription factor binding sites using the Match program (http://www.gene-regulation.de/).

Promoter Assay

A 1106-bp fragment (−1111 to −6) of the upstream from the initiation codon of the *NDUFV2* gene was amplified by PCR and cloned into the *MluI/BglII* site of pGL3-Basic vector (Promega, Madison, Wisconsin). Two kinds of reporter plasmids, having either −602G or −602A were prepared. A 586-bp fragment (−591 to −6) lacking the −602G> A site was also amplified and cloned into the same vector. Hela-S3 and HEK293 cells cultured in a 96-well plate were transfected using Superfect (Qiagen, Valencia, California) with .5 mg of the reporter plasmid, .05 mg of a reference plasmid (pRL-TK), and the pGL3-Basic vector carrying no insert. After 36 hours incubation, luciferase activities were measured with the aid of Dual-Glo luciferase assay system (Promega). Four independent experiments were performed for each condition, and the mean and SEM values were presented.

Results

We previously reported that −602G> A, among four polymorphisms (−796C> G, −795*T*> G, −602G> A, −233*T*> C) in the upstream region of *NDUFV2*, showed the significant association with BD (Washizuka et al 2003). In this study, four novel (−3542G> A, −3245*T*> C, −3041*T*> G, −2694A> G) and one known (−1020G> T) polymorphisms were detected by sequencing the upstream region extending up to 3963 bp of the transcription initiation site in the *NDUFV2*. We then genotyped these polymorphisms in Japanese patients with BD (n = 189) and control subjects (n = 222). The genotype frequencies of these five polymorphisms were in HWE in control subjects, although −3041*T*> C polymorphism was not in BDI patients, and −3245*T*> G was not in BDII patients. There was no significant difference of genotype frequencies of each SNP between male and female subjects. Detected polymorphisms in this study and in our previously reported polymorphisms (−796C> G, −795*T*> G, −602G> A, −233*T*> C, and 86C> T) were in strong linkage disequilibrium with each other (Table 1).

The genotype and allele distributions of the polymorphisms in Japanese population are shown in Table 2. The data for −602G> A polymorphism were cited from our previous paper (Washizuka et al 2003). Statistically significant differences in genotype distribution were observed between patients with BD and control subjects for −3041*T*> G (p = .001). The −3542G> A, −3245*T*> G, and −2694A> G polymorphisms showed significant genotypic association with BDII (p = .003, p = .002, and p = .006, respectively). These SNPs tended to be associated with BD or BDII even after Bonferroni correction. There was also a nominally significant difference in allelic distribution of −3041*T*> G polymorphism between patients with BDI and control subjects (p = .04).

Haplotype analysis consisting of all 10 polymorphisms revealed a statistically significant association in Japanese samples (global p < .0001). To explore which part of the *NDUFV2* gene

Table 3. Estimated Haplotype Frequencies of *NDUFV2* in Japanese Analyzed by Using the COCAPHASE Program

Haplotype[a]	Case	Frequency	Control	Frequency	χ^2	*P* Value	Common
A-A	244	.64	270	.61	.34	.55	+
G-A	3	.008	31	.07	20.35	<.0001	+
A-G	4	.01	37	.08	23.81	<.0001	+
G-G	127	.33	99	.22	10.79	.001	+
Global *P*						<.0001 (<.0001)[b]	

[a]Haplotypes of −3542G>A and −602G>A.
[b]The global *P* value in parentheses shows the global significance by permutation test.

contributes most to this overall association, we employed the sliding window approach in which each set of two or three consecutive polymorphisms were tested for association with BD (two- or three-marker haplotype analysis). This analysis showed evidence of association with BD in two limited regions around −3542G> A and −602G> A (most significant haplotype $p <$ .0001, global $p <$ .0001, and most significant haplotype $p =$ .008, global $p =$ .001, for the three-marker analysis, and global $p <$ .0001 and global $p =$ .002, respectively, for the two-marker analysis; Figure 1).

Because these two SNPs were located at the putative promoter region, we supposed that these polymorphisms might alter the transcription activity. At the beginning, we prepared a 3983bp fragment containing those two polymorphisms and tried to ligate this fragment into the pGL3-basic vector; this was not successful, however. Then we examined whether the −602G> A polymorphism had functional significance. Based on our previous analysis indicating that the two major haplotypes, C-T-A-T and C-T-G-T (consisting of −796C> G, −795*T*> G, −602G> A, and −233*T*> C polymorphisms of *NDUFV2*) were associated with BD, constructs of these two haplotypes were analyzed. Promoter activity was examined in two cell lines, Hela-S3 and HEK293. The transcription activity of the −602G construct was significantly higher than that of the −602A both in Hela-S3 and HEK293 ($p =$ .03 for Hela-S3, and $p =$ .05 for HEK293). The short construct lacking in the −602G> A site presented nearly equal activity of the −602A construct but had significantly smaller activity compared with the −602G construct ($p =$ .0009 and $p =$ .005, respectively; Figure 2).

Because we could not experimentally examine the functional significance of the −3542G> A, we examined whether this site affects the putative binding sites of transcription factors using the Match program. The −3542G> A was predicted to be within the putative binding site for HSF (heat shock transcription factor). HSF1 is known to affect the expression of several other nuclear encoded mitochondrial complex I subunit genes (e.g., *NDUFB8, NDUFA10, NDUFAB1,* and *NDUFS1*). Recently, the binding sequence of HSF1 was well characterized (TT*C*[*T*/C][G/*A*]*GAANNT*-*TC*[T/*C*]; the bases similar to this site of *NDUFV2* promoter was italicized; Trinklein et al 2004). When the −3542 site is G, the core sequence of putative binding site for HSF1, GAA, is lost, and probability of binding was predicted to be decreased.

Thus, the frequency of haplotypes consisting of −3542G> A and −602G> A polymorphisms was also estimated. Distributions of haplotype frequencies differed significantly between patients with BD and control subjects (global $p <$ .0001) (Table 3). Among the haplotypes, the G-G haplotype was significantly more frequently seen in BD ($p =$ .001), whereas G-A and A-G haplotypes were significantly less common in patients with BD compared with control subjects ($p <$ .0001). The results were basically similar when younger control subjects were excluded to match ages of the subjects.

We then performed a TDT in NIMH Genetics Initiative Bipolar Pedigrees. The distributions of genotypes of all 10 detected polymorphisms of the probands, fathers, and mothers were in HWE. We could not detect any allele that was significantly overtransmitted from patients to affected offspring in the NIMH trio samples of BD (Table 4).

We then examined the transmission of haplotypes consisting of −3542G> A and −602G> A polymorphisms from patients to affected offspring by using TDTPHASE program. We found significant association of the *NDUFV2* haplotypes with BD (global $p <$ .0001). Two haplotypes (G-A and A-G) tended to be undertransmitted in parents–proband trios of NIMH samples (nominal $p =$ .04 and $p =$ .01, respectively; Table 5).

Discussion

We identified four novel polymorphisms (−3542G> A, −3245*T*> G, −3041*T*> C, and −2694A> G) associated with BD in this study. Haplotype analysis revealed that two haplotype blocks surrounding the −3542G> A and −602G> A polymor-

Table 4. Transmission Disequilibrium Test in National Institute of Mental Health Initiative Bipolar Pedigrees

Polymorphism	Allele	Tr	Not Tr	Ratio	χ^2	*P*	Number of Trios
−3542G>A	G	20	27	.74	1.04	.30	85
−3245T>C	T	20	30	.67	2.00	.15	91
−3041T>G	T	39	44	.89	.30	.58	90
−2694A>G	A	19	26	.73	1.08	.29	81
−1020G>T	G	10	16	.63	1.38	.23	95
−796C>G	C	42	48	.88	.40	.52	94
−602G>A	G	31	24	1.29	.89	.34	98
−233T>C	T	43	50	.86	.52	.46	99
86C>T	C	34	25	1.36	1.37	.24	99

Tr, transmitted.

Table 5. Transmission of Haplotypes in National Institute of Mental Health Initiative Bipolar Pedigrees Analyzed by using TDTPHASE

Haplotype[a]	Tr	Frequency	Not Tr	Frequency	χ^2	P Value	Common
A-A	146	.84	137	.80	1.61	.20	+
G-A	<.01	<.01	3	.02	4.18	.04	+
A-G	<.01	<.01	4	.02	5.59	.01	+
G-G	26	.15	28	.16	.08	.76	+
Global P						.01 (.11)[b]	

[a]Haplotypes of −3542G>A and −602G>A.
[b]The global P value in parentheses shows the global significance by permutation test.

phisms were associated with BD. The haplotype of these two SNPs were significantly associated with BD in Japanese subjects. In NIMH trios, no individual SNP was associated, and the overtransmission of the risk haplotype in Japanese, G-G, was not observed. Although the observed trend of undertransmission of two haplotypes, G-A and A-G, might be due to the small number of trios, it is noteworthy that the trends of undertransmission of these two haplotypes seen in the NIMH bipolar trio samples were in the same direction to the significant decrease of these haplotypes in Japanese BD subjects.

Although the mechanism by which −602A> G changed the promoter activity is unknown, it would be of interest to note that the −602G polymorphism loses the putative binding site of a transcription factor, p300 (CCACTC). The finding that the −602G haplotype is more common in BD, although yielding a significantly higher promoter activity, is apparently inconsistent with our mitochondrial dysfunction hypothesis in BD; however, the direction of change of promoter activity in the luciferase assay cannot be directly compared with that in vivo. First, promoter activity can be affected by neighboring sequences because several transcription factors form a complex. When only a part of the promoter sequence is subcloned into the luciferase vector, as in this study, the promoter activity does not directly represent the activity in vivo. Second, regulation of gene expression is complex. Although we reported that mRNA expression of *NDUFV2* was decreased in the lymphoblastoid cells, Karry et al (2004) reported that the protein encoded by *NDUFV2* was up-regulated in autopsied BD brains. Thus, it cannot be concluded what kind of mitochondrial dysfunction is caused by polymorphisms of *NDUFV2* promoter. Even though the direction of the change may not represent the promoter activity in vivo, the results of promoter assay indicate that this region has some functional activity only when the −602 position is G.

We could not determine whether −3542G> A affects promoter activity, and this would be a worthwhile topic for future study. Because it has been reported that lithium enhances HSF1 activity (Carmichael et al 2002), it would be particularly interesting to examine the effects of HSF1.

It is most important to test whether the association of *NDUFV2* with BD is replicated using independent BD case–control or trio samples. In addition, 18p11 is a common linkage locus for BD and schizophrenia (Berrettini 2000; Lewis et al 2003), and mRNA and protein expression of *NDUFV2* is also altered in schizophrenia (Karry et al 2004). It would thus be interesting to examine the association between *NDUFV2* and schizophrenia.

In conclusion, the haplotypes consisting of −3542G> A and −602G> A polymorphisms in the upstream region of *NDUFV2* were associated with BD commonly in two ethnicities. Together with altered promoter activity, these findings indicate the role of *NDUFV2* as a genetic risk factor of bipolar disorder.

Data and biomaterials of the National Institute of Mental Health (NIMH) pedigrees were collected in four projects that participated in the NIMH Bipolar Disorder Genetics Initiative. From 1991 to 1998, the principal investigators and co-investigators were as follows: Indiana University, Indianapolis, Indiana, U01 MH46282, John Nurnberger, M.D., Ph.D., Marvin Miller, M.D., and Elizabeth Bowman, M.D.; Washington University, St. Louis, MO, U01 MH46280, Theodore Reich, M.D., Allison Goate, Ph.D., and John Rice, Ph.D.; Johns Hopkins University, Baltimore, Maryland U01 MH46274, J. Raymond DePaulo, Jr., M.D., Sylvia Simpson, M.D., MPH, and Colin Stine, Ph.D.; NIMH Intramural Research Program, Clinical Neurogenetics Branch, Bethesda, Maryland, Elliot Gershon, M.D., Diane Kazuba, B.A., and Elizabeth Maxwell, M.S.W.

Berrettini WH (2000): Susceptibility loci for bipolar disorder: Overlap with inherited vulnerability to schizophrenia. *Biol Psychiatry* 47:245–251.
Berrettini WH, Ferraro TN, Goldin LR, Detera-Wadleigh SD, Choi H, Muniec D, et al (1997): A linkage study of bipolar illness. *Arch Gen Psychiatry* 54:27–35.
Carmichael J, Sugars KL, Bao YP, Rubinsztein DC (2002): Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. *J Biol Chem* 277:33791–33798.
de Coo R, Buddiger P, Smeets H, Geurts van Kessel A, Morgan-Hughes J, et al (1995): Molecular cloning and characterization of the active human mitochondrial NADH: Ubiquinone oxidoreductase 24-kDa gene (*NDUFV2*) and its pseudogene. *Genomics* 26:461–466.
Gershon ES, Bander JA, Detera-Wadleigh SD, Ferraro TN, Berrettini WH (1996): Maternal inheritance and chromosome 18 allele sharing in unilineal bipolar illness pedigrees. *Am J Med Genet* 67:202–207.
Goodwin FK, Jamison KR (1990): *Manic-Depressive Spectrum*. New York: Oxford University Press.
Hattori N, Suzuki H, Wang Y, Minoshima S, Shimizu N, Yoshino H, et al (1995): Structural organization and chromosomal localization of the human nuclear gene (*NDUFV2*) for the 24-kDa iron-sulfur subunit of complex I in mitochondrial respiratory chain. *Biochem Biophys Res Commun* 216:771–777.
Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, Kusumi I, et al (2003): Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. *Nat Genet* 35:171–175.
Karry R, Klein E, Ben Shachar D, (2004): Mitochondrial complex I subunits expression is altered in schizophrenia: A postmortem study. *Biol Psychiatry* 55:676–684.
Kato T, Kato N (2000): Mitochondrial dysfunction in bipolar disorder. *Bipolar Disord* 2:180–190.
Kato T, Kunugi H, Nanko S, Kato N (2001): Mitochondrial DNA polymorphisms in bipolar disorder. *J Affect Disord* 62:151–164.
Kato T, Stine OC, McMahon FJ, Crowe RR (1997): Increased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder. *Biol Psychiatry* 42:871–875.
Kato T, Takahashi S, Shioiri T, Inubushi T (1993): Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. *J Affect Disord* 27:53–59.
Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al (2003): Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. *Am J Hum Genet* 73:34–48.

Nakatani N, Aburatani H, Nishimura K, Semba J, Yoshikawa T (2004): Comprehensive expression analysis of a rat depression model. *Pharmacogenomics J* 4:114–126.
Nothen MM, Cichon S, Rohleder H, Hemmer S, Franzek E, Fritze J, et al (1999): Evaluation of linkage of bipolar affective disorder to chromosome 18 in a sample of 57 German families. *Mol Psychiatry* 4:76–84.
Pritchard JK, Stephens M, Donnelly P (2000): Inference of population structure using multilocus genotype data. *Genetics* 155:945–959.
Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger JI, et al (2003): Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. *Am J Hum Genet* 73:49–62.
Smeitink J, Sengers R, Trijbels F, van den Heuvel L (2001): Human NADH: ubiquinone oxidoreductase. *J Bioenerg Biomembr* 33:259–266.
Stine OC, Xu J, Koskela R, McMahon FJ, Gschwend M, Friddle C, et al (1995): Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect. *Am J Hum Genet* 57:1384–1394.
Trinklein ND, Murray JI, Hartman SJ, Botstein D, Myers RM (2004): The role of heat shock transcription factor 1 in the genome-wide regulation of the mammalian heat shock response. *Mol Biol Cel* 15:1254–1261.
Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Martin R, et al (1999): Lithium responsive bipolar disorder, unilineality and chromosome 18: A linkage study. *Am J Med Genet* 88:411–415.
Washizuka S, Kakiuchi C, Mori K, Kunugi H, Tajima O, Akiyama T, et al (2003): Association of mitochondrial complex I subunit gene *NDUFV2* at 18p11 with bipolar disorder. *Am J Med Genet* 120B:72–78.